Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bjs/znac376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy.
Euroasian J Hepatogastroenterol
December 2024
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India.
Background: The purpose of the present study was to evaluate clinicopathological characteristics, patterns of recurrence, survival outcomes, and implications for the addition of chemoradiotherapy for patients with resected perihilar and intrahepatic cholangiocarcinoma (CCA).
Materials And Methods: For the present retrospective study, we identified 38 and 10 patients with resected perihilar and intrahepatic CCA. In perihilar CCA, adjuvant treatment was given as chemotherapy ( = 13) or chemoradiotherapy ( = 10).
Iodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma.
J Control Release
December 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China; Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, China. Electronic address:
Transarterial radioembolization (TARE) is a recommended locoregional strategy for intermediate hepatocellular carcinoma (HCC), whereas, the effect is insufficient to reverse the immunosuppression tumor microenvironment, and the overall benefits for patients remain to be improved. In this study, a multifunctional microsphere (MS) I-ICT/R848-MS is developed to propose an approach combined with TARE, icaritin (ICT) and immune modulator resiquimod (R848). ICT and iodine-131 (I) radiation can induce immunogenic cell death, which, in combination with R848, will boost dendritic cell (DC) maturation.
View Article and Find Full Text PDFCase report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response.
Front Immunol
December 2024
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Pancreatic adenosquamous carcinoma (PASC) is a rare subtype of pancreatic cancer (PC), with no established consensus on the optimal treatment for postoperative liver metastasis recurrence. We report a case of a 48-year-old male patient who underwent radical surgery and was pathologically diagnosed with microsatellite instability-high (MSI-H) PASC. The patient experienced liver metastasis recurrence following single-agent gemcitabine adjuvant chemotherapy.
View Article and Find Full Text PDFEmbolic and Ablative Therapy for Hepatocellular Carcinoma.
Clin Liver Dis
February 2025
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Article Synopsis
- Locoregional therapies (LRTs) for hepatocellular carcinoma include ablative methods like microwave and radiofrequency ablation, as well as embolic techniques such as transarterial chemoembolization and radioembolization.
- These therapies aim to either cure, bridge, or downstage patients, but they often face challenges with high post-treatment recurrence rates.
- Current research suggests that combining LRTs with systemic therapy could enhance disease control and improve outcomes for patients with liver cancer.
Systemic Therapy for Hepatocellular Carcinoma.
Clin Liver Dis
February 2025
Department of Medicine, Division of Medical Oncology, Duke University Health System, Durham, NC, USA. Electronic address:
Systemic therapy for hepatocellular carcinoma has evolved from sorafenib to now include immune checkpoint blockade, either atezolizumab/bevacizumab or durvalumab/tremelimumab, and soon to include camrelizumab/rivoceranib and nivolumab/ipilimumab. Second-line therapy remains predominantly either a multikinase inhibitor or ramucirumab. Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!